Certara Past Earnings Performance
Past criteria checks 2/6
Certara has been growing earnings at an average annual rate of 3.2%, while the Healthcare Services industry saw earnings growing at 16.5% annually. Revenues have been growing at an average rate of 11% per year. Certara's return on equity is 0.7%, and it has net margins of 2%.
Key information
3.16%
Earnings growth rate
6.78%
EPS growth rate
Healthcare Services Industry Growth | 1.72% |
Revenue growth rate | 10.99% |
Return on equity | 0.75% |
Net Margin | 1.97% |
Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
A Look At The Fair Value Of Certara, Inc. (NASDAQ:CERT)
Sep 04Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings
Aug 14Some Investors May Be Worried About Certara's (NASDAQ:CERT) Returns On Capital
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Jul 18Is Certara (NASDAQ:CERT) Using Too Much Debt?
Jun 27
FDA Phaseout And AI Integration Will Expand Biosimulation Demand
Regulatory shifts and long-term outsourcing trends are boosting demand for Certara's biosimulation and data-driven modeling solutions, supporting recurring revenue growth and market expansion.Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around
May 07Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues
Apr 15Buy Certara After The FDA Announcement
Apr 11Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching
Mar 29Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly
Feb 27Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up
Jan 11Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?
Dec 19Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return
Nov 15Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?
Oct 24Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly
Sep 20Certara: Still Awaiting Consistent Growth
Sep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate
Aug 31There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price
Jul 18Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital
Jun 13When Should You Buy Certara, Inc. (NASDAQ:CERT)?
Apr 11Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk
Mar 21Returns Are Gaining Momentum At Certara (NASDAQ:CERT)
Feb 17Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
Jan 30Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)
Dec 07Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Oct 31Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Sep 17An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued
Aug 30Revenue & Expenses Breakdown
How Certara makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 25 | 406 | 8 | 125 | 36 |
31 Mar 25 | 394 | -3 | 124 | 36 |
31 Dec 24 | 385 | -12 | 121 | 37 |
30 Sep 24 | 373 | -31 | 117 | 37 |
30 Jun 24 | 364 | -79 | 112 | 38 |
31 Mar 24 | 361 | -61 | 95 | 37 |
31 Dec 23 | 354 | -55 | 94 | 34 |
30 Sep 23 | 353 | -34 | 94 | 33 |
30 Jun 23 | 352 | 19 | 93 | 30 |
31 Mar 23 | 344 | 14 | 100 | 30 |
31 Dec 22 | 336 | 15 | 97 | 28 |
30 Sep 22 | 324 | -4 | 87 | 28 |
30 Jun 22 | 314 | -10 | 95 | 26 |
31 Mar 22 | 301 | -12 | 93 | 23 |
31 Dec 21 | 286 | -13 | 88 | 20 |
30 Sep 21 | 275 | -58 | 134 | 24 |
30 Jun 21 | 262 | -55 | 120 | 23 |
31 Mar 21 | 253 | -49 | 111 | 21 |
31 Dec 20 | 244 | -49 | 106 | 20 |
30 Sep 20 | 233 | -1 | 60 | 12 |
30 Jun 20 | 226 | 1 | 58 | 12 |
31 Mar 20 | 215 | -5 | 57 | 12 |
31 Dec 19 | 209 | -9 | 53 | 12 |
31 Dec 18 | 164 | -33 | 51 | 10 |
Quality Earnings: CERT has a large one-off loss of $6.9M impacting its last 12 months of financial results to 30th June, 2025.
Growing Profit Margin: CERT became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CERT has become profitable over the past 5 years, growing earnings by 3.2% per year.
Accelerating Growth: CERT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CERT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (13.2%).
Return on Equity
High ROE: CERT's Return on Equity (0.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/10/01 15:13 |
End of Day Share Price | 2025/10/01 00:00 |
Earnings | 2025/06/30 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Certara, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joseph Vruwink | Baird |
Luke Sergott | Barclays |
Andrew Moss | BofA Global Research |